U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07381829) titled 'A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer' on Dec. 09, 2025.
Brief Summary: Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for subsequent studies.
Study Start Date: Oct. 27, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor Cancer
Intervention:
DRUG: HC010
HC010 once every 3 weeks (Q3W) by intravenous drip
DRUG: Paclitaxel (Chemotherapy)
the combination chemotherapy regimens are al...